- Epidemiology and Global Health
- Medicine
Third SARS-CoV-2 vaccination appears to eliminate disparities in anti-Spike antibodies between those who received Pfizer-BioNTech versus Oxford/AstraZeneca for first and second vaccination, but levels remain lower in certain groups such as those on the UK 'Shielded Patient List'.